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1. Introduction 
Sulfated mucopolysaccharides, such as heparin, 
heparan sulfate, chondroitin sulfates and dermatan 
sulfate, have been shown to be normal constituents of 
animal tissues and body fluids. Their biological 
functions are not yet known with certainty. A role as 
lubricants in the living organism was ascribed to these 
sulfated mucopolysaccharides due to their highly 
viscous and elastic properties in solution. Heparin 
displays anticoagulant and anti-lipaemic properties 
[ 11. Direct effects on various enzymes have been 
described for polyelectrolytes including heparin and 
other sulfated glycosaminoglycans [2,3]. Wolff and 
Cook [4] have recently described the effects of poly- 
cations (RNAase A, spermin, spermidine and poly- 
lysine) and of polyanions (Dextran sulfate, Suramin 
and polyaspartic acid) on bovine thyroid-stimulating- 
hormone-sensitive adenylate cyclase. 
Hyaluronic acid and chondroitin sulfuric acid were 
shown to be constituents of the follicular fluid in the 
bovine ovary [5] . We have recently shown that heparin- 
like substances as well as chondroitin+ulfate, 
chondroitin-6-sulfate and dermatan sulfate are syn- 
thesized and accumulate in the rat ovary [6,7]. In 
searching for a functional role for ovarian glycosamino- 
glycans we examined the possibility that these sub- 
stances may modulate the activity of the LH-stimulated 
adenylate cyclase in the follicle, and thus participate 
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in controlling ovulation-related events in the ovary. 
This hormone-sensitive enzyme is known to be 
stimulated equally well by both LH and hCG [8]. 
These hormones have also been shown to compete for 
the same receptor sites in this tissue [9] . 
In this study, we demonstrate that the sulfated 
glycosamineglycans, heparin, heparan sulfate and 
dermatan sulfate, are potent inhibitors of ovarian 
adenylate cyclase. Heparin was the most effective 
inhibitor, and was shown to inhibit LH/hCC stimulated 
ovarian adenylate cyclase but had only a small effect 
on enzyme activity when assayed in the absence of 
these hormones or when stimulated by NaF. The data 
presented here suggest a selective effect of heparin on 
the hormone receptor level or its coupling to adenylate 
cyclase, thus providing a new tool for the analysis of 
receptor enzyme interations. 
2. Materials and methods 
[c~-~‘P]ATP, adenosine 3’5’cyclic monophosphate, 
dithiothreitol, GTP, creatine phosphate, creatine phos- 
phokinase and dextran sulfate (mol wt - 500 000) 
were from Sigma Chemical Corp. Ovine LH (NIH-LH- 
Sl 8) was kindly supplied by the US NIH Hormone 
Distribution Center. Pregnant mare serum gonado- 
tropin (PMSG: Gestyl, NV) was purchased from 
Organon, Oss, Holland. Human chorionic gonado- 
tropin 13 700 IU/mg was from Serono, Rome. 
Sodium heparin grade B 159 U/mg was from Cal- 
biochem. Highly purified heparan sulfate, and highly 
purified dermatan sulfate were kindly supplied by 
Dr M. B. Marthews, University of Chicago, under a 
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contract (NOl-AM-S-2205) from the US NIH (NIAMD) 
Polyglutamic acid (mol wt - 10 000) was a gift from 
Dr N. Lotan, Weizmann Institute of Science. 
Wistar-derived female rats 25 days old were given 
a single injection (1.5 IU) PMSG at 11.00-l 2.00 a.m. 
in order to increase the amount of ovarian LH- 
stimulatable adenylate cyclase activity [lo] . Ovaries 
were excised 48 h later and plasma membranes were 
prepared by modification [ 111 of the method described 
by Neville [ 121 . Adenylate cyclase assays were 
performed as described [ 131. Protein was determined 
according to Lowry et al. [ 141 using bovine serum 
albumin as standard. 
3. Results 
Heparin (10 pg/ml) essentially abolished the activity 
of rat ovarian adenylate cyclase when stimulated by 
hCG (fIg.1) or by LH (fig.2). Inhibition was dose- 
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Fig.1. Inhibition of ovarian adenylate cyclase activity by 
heparin. The reaction mixture (final vol. 50 ~1) contained: 
Tris acetate, pH 7.6, 25 mM: magnesium acetate, 5 mM; 
[cz-~~P]ATP, 0.5 mM (2-6 X IO6 cpm); adenosine 3’,5’- 
cyclic monophosphate, 0.05 mM; dithiothreitol, 1 mM; GTP, 
0.01 mM, creatine phosphate, 5 mM; creatine phosphokinase, 
50 U/ml and heparin at the concentration indicated. When 
added hCG was 5 i.u/ml and NaF 10 mM. The reaction was 
initiated by the addition of purified ovarian plasma 
membranes (3.7 pg protein/assay tube) and terminated after 15 
min incubation at 30°C. Activity determined in the absence 
of LH is referred to as basal adenylate cyclase activity. Points 
represent mean values of duplicate assays; deviation within 
pair did not exceed 10%. 
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Fig.2. The inhibitory action of various polyanions on ovarian 
adenylate cyclase activity. The effect of heparin (Hep), 
dermatan sulfate (DS), heparan sulfate (HS), dextran sulfate 
(Dex S) and polyglutamic acid (Poly glu) on adenylate 
cyclase activity was determined as described in legend to fig.1 
using 5.0 fig plasma membrane protein/assay tube. 
dependent over the range of I-10 pg/ml, reaching 
50% at a heparin-concentration of 2 pg/ml (fig.1). 
Hormone-stimulatable adenylate cyclase activity 
appeared to be more susceptible to the inhibitory 
action of heparin than was basal activity. At a con- 
centration of 10 pg/ml heparin reduced hCG-sensitive 
adenylate cyclase activity to one-tenth and basal 
activity to one-third, and had only a marginal effect 
(15% inhibition) on NaF stimulated activity (fig.1) 
indicating a rather selective effect on the hormone- 
stimulatable adenylate cyclase activity. Other glycos- 
aminoglycans when tested at concentrations of up to 
100 pg/ml were also inhibitory, but to a lesser degree 
(fig.2). It was interesting to note that highly purified 
heparan sulfate which is structurally related to heparin 
[l] , was much less effective and inhibited LH- 
dependent activity by only 66% at a concentration of 
100 pg/ml, compared with 82% inhibition by heparin 
at a much lower concentration (10 pg/ml). Highly 
purified dermatan sulfate inhibited LH-sensitive 
enzyme activity by 38% at a concentration of 10 pg/ 
ml and by 76% at 100 ,ug/ml. The sulfated mucopoly- 
saccharides chondroitin+sulfate and chondroitin-6- 
sulfate, as well as the non-sulfated glycosaminoglycan 
hyaluronic acid were found to be without effect on 
adenylate cyclase even at concentrations of 100 pg/ml 
(data not shown). Two synthetic polyanions were 
tested for their effect on the LH-sensitive adenylate 
cyclase activity. Dextran sulfate at a concentration of 
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10 pg/ml inhibited 77% of the LH-simulatable activity, 
while polyglutamic acid exerted only a weak inhibitory 
action (25% loss of activity) at a concentration of 
100 pg/ml (fig.2). 
4. Discussion 
This study demonstrates that heparin, and to a 
lesser extent, dermatan sulfate and heparan sulfate, 
inhibit the activity of LH-sensitive adenylate cyclase 
of the rat ovary. Other sulfated glycosaminoglycans 
such as chondroitin-4-sulfate and chondroitin-6- 
sulfate, and the non-sulfated substance hyaluronic 
acid were found to be without effect. This finding is 
suggestive of a selective effect which may be related 
to the degree of sulfation and the proximity of the 
sulfate groups to each other on the sugar backbone 
[ 1,151. The inhibitory effect could not be attributed 
solely to the nonspecific action of negative charges, 
since polyglutamic acid, a negatively charged poly- 
peptide, was only slightly inhibitory. 
Hormone-dependent adenylate cyclase activity 
was more susceptible to the inhibitory action of 
heparin than was basal activity. In the presence of 
NaF, adenylate cyclase activity was hardly effected. 
The relative resistance of catalytic activity in the 
absence of hormone (i.e., basal and NaF) suggests 
that heparin acts mainly at the hormone receptor 
level. This is further supported by the finding that 
hormone binding to this membrane preparation was 
inhibited selectively by those glycosaminoglycans 
which exerted inhibitory action on adenylate cyclase 
activity (Salomon, Y. and Amsterdam, A., 
unpublished). However, the inhibitory action on basal 
enzyme activity, though more limited, suggests that 
heparin also exerts a direct action on adenylate cyclase. 
Wolff and Cook [4] described an inhibitory action 
of dextran sulfate on thyroid-stimulating-hormone- 
sensitive adenylate cyclase of bovine thyroid gland. 
This indicates that the inhibitory action of sulfated 
polyanions is not restricted to ovarian adenylate 
cyclase. However, the inhibitory action of naturally 
occurring glycosaminoglycans on adenylate cyclase in 
other tissues has to be established. Heparin modified 
catalytic parameters of soluble monomeric enzymes, 
such as trypsin [3] , amylase and ribonuclease [2]. AS 
shown in this study, heparin influenced mainly regula- 
tory properties of the membrane bound adenylate 
cyclase, an enzyme which is generally believed to be a 
multicomponent structure. Being a negatively charged 
polymer it is not unlikely that by adsorbing to opposite 
charges exposed on the surface of the plasma mem- 
brane, heparin may also restrict the lateral mobility 
of the components of adenylate cyclase, thus inter- 
fering with its normal function. Heparin therefore 
represents a new potential tool for the study of 
receptor enzyme interactions. 
The occurrence of heparin-like substances and 
dermatan sulfate in the rat ovary was recently 
described in our laboratory [6,7]. It is therefore 
tempting to suggest hat these substances might play 
a regulatory role in ovulation-related events by affect- 
ing the activity of adenylate cyclase in the ovary. 
Degradation of ovarian mucopolysaccharides at late 
stages of follicular maturation has been demonstrated 
[5,16] . Since the barrier between the follicular tissue 
and the vascular system is highly permeable [17,18], 
it is likely that the resulting breakdown products may 
be readily removed, thus permitting activation of LH- 
sensitive adenylate cyclase. Interestingly, polycystic 
ovaries, which fail to ovulate, are characterized by 
abnormally high levels of acid mucopolysaccharides 
[191. 
To the best of our knowledge, this is the first 
description of a well-defined inhibitor of adenylate 
cyclase naturally occurring in body fluids. Whether 
heparin and related substances also participate in 
regulation of adenylate cyclase activity in other tissues 
in which they are abundant, e.g., liver, lung and 
arterial wall, is an issue which should be investigated. 
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